Lisata Therapeutics
LSTA
24 hedge funds and large institutions have $1.52M invested in Lisata Therapeutics in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
4% more funds holding
Funds holding: 23 → 24 (+1)
0% less ownership
Funds ownership: 0.53% → 0.53% (-0%)
27% less capital invested
Capital invested by funds: $2.08M → $1.52M (-$565K)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
STA
Summit Trail Advisors
New York
|
+$45.8K |
| 2 |
Renaissance Technologies
New York
|
+$40.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.39K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$3.76K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$2.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$51K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$25K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.44K |
| 4 |
Morgan Stanley
New York
|
-$272 |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$39 |
LSTA Hedge Fund Activity: Q1 2020 in Review
24 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2020, worth a combined $1.52M — down 27% from $2.08M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LSTA positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Summit Trail Advisors, opening a new position worth an estimated $45.8K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $51K sold.
- 24 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2020, up from 23 in Q4 2019.
- Funds reported $1.52M of Lisata Therapeutics stock for Q1 2020, down 27% quarter-over-quarter.
- 5 funds opened new Lisata Therapeutics positions in Q1 2020 and 2 closed out, a net change of +3 holders.
- The largest Lisata Therapeutics buyer in Q1 2020 was Summit Trail Advisors, an estimated $45.8K added.
- The largest Lisata Therapeutics seller in Q1 2020 was Susquehanna International Group, an estimated $51K sold.
Based on aggregated 13F filings for Q1 2020.